GPCR/G protein

All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B6878 Ro 60-0175 fumarateSummary: 5-HT2 receptor agonist -
C3632 ZilpaterolSummary: β-adrenergic receptor agonist -
B6863 Altanserin hydrochlorideSummary: 5-HT2A receptor antagonist -
C3347 Isoxsuprine (hydrochloride)Summary: β-adrenergic receptor modulator -
B6859 WAY 161503 hydrochlorideSummary: 5-HT2C receptor agonist -
C3067 Niguldipine (hydrochloride)Summary: α1A-adrenoceptor antagonist -
B6858 Zacopride hydrochlorideSummary: 5-HT3 receptor antagonist and 5-HT4 receptor agonist -
C3031 (R)-(+)-AtenololSummary: less active enantiomer of the racemic β1-adrenergic receptor antagonist, (R,S)-atenolol. -
B6842 R-96544 hydrochlorideSummary: 5-HT2 receptor antagonist -
C3021 L-PhenylephrineSummary: adrenergic α1A receptor agonist
